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This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
Medicine 2015 and co-published as a series in Critical
Care. Other articles in the series can be found online
at http://ccforum.com/series/annualupdate2015.
Further information about the Annual Update in
Intensive Care and Emergency Medicine is available
from http://www.springer.com/series/8901.modern care for ARDS requires a decision to maximallyIntroduction
Despite new promising therapeutic interventions includ-
ing protective ventilation, prone positioning, use of
neuromuscular blockers and conservative fluid balance,
acute respiratory distress syndrome (ARDS) remains a
devastating disease [1,2]. Mortality rates for ARDS have
decreased over time but still remain around 40%, in
large part a result of the hemodynamic complications of
this syndrome [3]. ARDS has various etiologies and early
diagnosis and intervention are key to improving out-
comes [4]. Dominant features of ARDS include injury to
the alveolar-capillary membrane, which results in severe
hypoxemia, decrease in pulmonary compliance, and in-
crease in pulmonary vascular resistance [5,6]. At present,
positive-pressure mechanical ventilation is the mainstay
of symptomatic treatment for ARDS [1], but may further
increase pulmonary hypertension and right ventricular
(RV) afterload, leading to acute cor pulmonale and RV
failure [6]. Moreover, mechanical ventilation induces
additional lung injuries due to overdistention, repeated
stretch to the alveoli, atelectotrauma, and increased in-
flammatory mediator levels [7]. The ARDSNet study re-
ported a reduction in mortality with a ventilation
strategy involving limitation of mean tidal volume to 6
ml/kg, as compared with a more traditional tidal volume* Correspondence: ph.morimont@chu.ulg.ac.be
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reuse must be sought from the publisher.of 12 ml/kg [1]. However, utilization of lower tidal vol-
umes leads to permissive hypercapnia and most clini-
cians seldom use very low tidal volumes in practice.
Indeed, the need to substantially reduce tidal volume to
improve outcome in ARDS patients remains question-
able because of the deleterious effects of hypercapnia
[8]. In addition, lung injury persists even when tidal vol-
umes are small [9] and further reduction in tidal volume
beyond those recommended by ARDSNet may have out-
come benefits [10], although not all agree [11]. Thus,
reduce ventilator settings to ensure lung protection and
reduce exacerbation of lung injury while facing the
metabolic consequences of this intervention. How can
we enhance lung protection in ARDS while not causing
metabolic disturbances?
As the discussion about optimization of mechanical
ventilation in ARDS patients continues, a new promising
adjunct is low-flow partial lung support or extracorpor-
eal CO2 removal (ECCO2R). This approach takes advan-
tage of a concept proposed many years ago [12] which,
carried out with modern technology, has been shown to
effectively remove metabolically produced CO2 while
permitting significant reductions in minute ventilation
in preclinical [13,14] and clinical settings [15]. Specific-
ally, combination therapy using reduction in tidal vol-
umes to around 4 ml/kg and concomitant use of
ECCO2R has been shown to effectively manage permis-
sive hypercapnia in ARDS [15]. Thus ECCO2R could be
an effective strategy in ARDS management and a viable
option to combat the deleterious effects of low-tidal vol-
ume ventilation, such as permissive hypercapnia.
The purpose of this manuscript is to elaborate on po-
tential applications of ECCO2R as an adjunct to mech-
anical ventilation for the treatment of ARDS. We discuss
the effects of hypercapnia in ARDS and the emerging
evidence for the utility of ECCO2R during hypercapnia;
as well as the potential role of ECCO2R in optimizing
RV-pulmonary artery coupling and RV function in lung
failure.his article is co-published by agreement with Springer-Verlag. Permission for
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Cellular and metabolic effects
Depending on its degree and duration, permissive hyper-
capnia has a series of potential adverse effects related to
systemic and cerebral vasodilatation, cardiovascular de-
pression, arrhythmia, and increase in gastric hydrogen
ion secretion [16]. Until recently, however, cellular and
metabolic effects of hypercapnia in ARDS have not been
clearly defined. Some investigators have hypothesized
that hypercapnia per se might improve outcome in
ARDS and have proposed the concept of ‘therapeutic’
hypercapnia [17]. The logic of this approach is that since
inflammation contributes to respiratory failure and
ARDS and respiratory acidosis has been shown to inhibit
several inflammatory mediators [18], it seems reasonable
that hypercapnia may be protective in ARDS. In support
of this concept, hypercapnia has been demonstrated to
attenuate acute lung injury induced by free radicals, pul-
monary and systemic ischemia-reperfusion, pulmonary
endotoxin, and excessive lung stretch [19]. These effects
seem to be due in part to the anti-inflammatory effects
of hypercapnia, including attenuation of neutrophil func-
tion, reduction in free radicals, decreased oxidant-
induced tissue damage, and reduction in the levels of
pro-inflammatory cytokines, such as tumor necrosis fac-
tor (TNF)-α, interleukin (IL)-1 and IL-8 [20]. However,
some of these beneficial effects were likely caused by
systemic acidosis rather than hypercapnia per se, because
buffering of respiratory acidosis worsened experimental
lung injury [21]. Recent studies confirm that CO2 can
also act as a signaling molecule via pH-independent
mechanisms, leading to deleterious effects in the lung.
These effects include inhibition of cell membrane repair,
impairment of alveolar fluid clearance, and suppression of
innate immunity and host defense [19]. Briva et al. [22]
showed that elevated CO2 levels impaired Na,K-ATPase
function independently of extra- and intra-cellular acid-
osis. Taken together, the above reports do not suggest
convincingly that hypercapnia could be beneficial and
means to mitigate excessive CO2 accumulation in the
blood are likely to be useful tools in the arsenal of med-
ical providers.
Hypercapnia, pulmonary hemodynamics and right
ventricular function
Hypercapnic acidosis enhances pulmonary vasoconstric-
tion [23]. Several clinical studies demonstrated that hyper-
capnic acidosis causes an increase in mean pulmonary
arterial pressure in ARDS [6]. Acute pulmonary hyperten-
sion increases RV afterload [24,25], which individually and
collectively with microvascular obstruction, the effects of
positive-pressure ventilation, and hypercapnic acidosis ex-
acerbate RV failure in ARDS [6]. Acute cor pulmonale inARDS patients is associated with high mortality rates [6].
Impaired RV function in early stage ARDS may be under-
diagnosed and yet it might be the harbinger of a down-
ward spiral in the patient’s condition [6]. We previously
established that pulmonary vascular resistance and RV
ejection fraction (RVEF) are poor indicators of RV-arterial
performance [24]. RV-arterial coupling is beneficial for
cardiovascular performance and can be assessed by the
ratio of two elastances: Ees/Ea, where Ees is the RV elas-
tance characterizing the RV system and Ea is the arterial
elastance characterizing the pulmonary vascular system.
When Ees/Ea is > 1, the system is coupled. However,
when Ees/Ea is < 1, the cardio-pulmonary system is
uncoupled [24]. Thus, the Ees/Ea ratio reflects the
mechano-energetic aspects of RV-vascular coupling. It
can be demonstrated that efficiency of energy transfer
from the RV to the pulmonary circulatory system is opti-
mal when Ees/Ea = 2 whereas mechanical RV work is
maximal when Ees/Ea = 1 [26]. In ARDS patients, in-
creased RV afterload is responsible for increased Ea while
Ees may decrease because of hypercapnic acidosis, hyp-
oxia, and often associated sepsis, leading to uncoupling
between the right ventricle and the pulmonary circula-
tion, and finally precipitating RV failure (Figure 1) [27].
Therapies should ideally be oriented to restore the coup-
ling between the heart and pulmonary vasculature by
avoiding any increase in pulmonary vascular tone as well
as depression in RV contractility [27,28]. Alternatively,
safe adjuncts to current ARDS management approaches
should be considered as we learn more about the pros
and cons of hypercapnia in ARDS.
New extracorporeal devices for CO2 removal
The premise of intervening with the ventilatory function
of the lung stems from early work by Kolobow, Gattinoni
and Pesenti, which showed that partial-to-total CO2 re-
moval and so ‘ventilation’ is possible by means of extracor-
poreal circulation of the blood through a gas exchange
membrane [12,29,30]. Of all the available forms of extra-
corporeal gas exchange, partial lung support, also known
as ECCO2R or respiratory dialysis, is the most promising,
because it offers unique advantages while carrying a low
potential for complications [31,32]. In this context, the re-
cent successes of full extracorporeal membrane oxygen-
ation (ECMO) are also relevant as lung support with full
ECMO can replace total lung function to include oxygen-
ation and ventilation. Although full ECMO can also be
used for ‘ventilation’ or as an ECCO2R approach, it comes
at a higher logistical and economic burden [33] when
compared to use of special ECCO2R devices which, in
contrast to ECMO, are logistically simpler and do not re-
quire dedicated personnel, reducing the cost of care. Al-
though the question about whether various lung support

















Figure 1 Schematic representation of the key role played by hypercapnic acidosis in right ventricular (RV) failure in patients with
acute respiratory distress syndrome (ARDS). PEEP: positive end-expiratory pressure.
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termined [34], partial lung support via ECCO2R at flows
of 300–500 ml/min has already been shown to provide re-
placement of about 50% or more of the ventilatory func-
tion of the lung [13] and poses a viable therapeutic
adjunct to mechanical ventilation. ECCO2R significantly
reduces mechanical ventilator settings while successfully
combating hypercapnia and acidosis in humans with
ARDS [13,15]. When compared to oxygenation, removal
of CO2 from blood can be accomplished at lower blood
flows [35]. As a result, less invasive veno-venous devices
have been specifically designed for CO2 removal with
high gas exchange efficiency at relatively low blood flow
rates (300–1,500 ml/min). Theoretically, flow rates as
low as 0.5 l/min should be enough to eliminate all the
CO2 that the body produces, because a liter of blood
with a PaCO2 of 5 kPa contains around 500 ml of CO2
or on average two times more CO2 than the body pro-
duces per minute. However, the exact level of CO2 re-
moved will depend on several factors – mainly blood
flow through the circuitry and the CO2 level before the
membrane [36].
There is an increasing number of modern ECCO2R
devices on the market. These devices use 13–17 F veno-
venous dual lumen catheters which can be placed percu-
taneously using the Seldinger technique. The ECCO2R
circuitry is heparin-coated, which reduces heparinization
requirements. These ECCO2R devices use advanced low
impact mechanical pumps to propel the blood and effi-
cient hollow-fiber gas exchangers or membrane lungs.The micropores in the membrane lungs create micro-
scopic blood-gas interfaces allowing efficient gas ex-
change on a counter-current principle with sweep gas
blown through the blood-polymer interface. As micro-
pores also cause plasma leak, non-microporous poly-4-
methyl-1-pentene has been recently established as a
standard material for gas exchangers, providing better
gas exchange, better bio compatibility and less plasma
leak compared to older silicone or polypropylene mate-
rials [37]. Fibers in the membrane lungs are arranged
into a complex mat allowing optimal blood flow and im-
proving gas transfer efficiency by enhancing diffusion.
Membranes are also coated with covalently bound hep-
arin to enhance biocompatibility and reduce thrombo-
genicity. Modern membrane lungs achieve adequate gas
exchange with surface areas of 0.67 to 3 m2. Rotary
pumps used in modern ECCO2R devices are either cen-
trifugal or diagonal flow pumps designed to minimize
blood trauma. To eliminate the need for a drive shaft or
bearings and to reduce heating, most advanced centrifu-
gal pump impellors are completely suspended in an elec-
tromagnetic field which reduces shear stress. The pump
and membrane lung are either separate components or
incorporated into a single console. Most importantly,
the design and components of the modern veno-venous
(VV)-ECCO2R systems reduce the degree of anticoagu-
lation required and minimize the damaging effects of
blood coming into contact with foreign surfaces. There
are currently four commercially available VV-ECCO2R
systems, all approved for use in Europe but none with
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1. The Pump-Assisted Lung Protection (PALP)
(Maquet, Rastatt, Germany) system is a low-flow
system based on Maquet’s CARDIOHELP® console,
which is a portable heart–lung support system.
PALP is not an ECMO device and has been designed
to serve as a partial lung support device with
primary effect on the side of CO2 removal (Figure 2a).
However, the PALP can be seamlessly bridged into full
ECMO by simply switching out the membrane for a
full ECMO oxygenator while using the same
operational console which can travel with the patient.
The latter is a unique feature of the Maquet system
and constitutes a mobile partial lung support to total
lung support solution.
2. The iLA Activve® (Novalung, Germany) is based on
the same principle (Figure 2a), but uses a small
portable diagonal pump and operational console and
has the capacity to run at low or high flow rates
(0.5–4.5 l/min). It covers the full range of
respiratory support from highly effective CO2
elimination at lower flows to complete oxygenation
and ventilation support. This capability is similar to
the Maquet system in the sense that the footprint of
therapy can be increased from partial to full lung
support.
3. The Hemolung® system (Alung Technologies,
Pittsburgh, USA) has a small 0.67 m2 surface area
and is the only system specifically designed for CO2
removal and targeting CO2 retention syndromes,
such as chronic obstructive pulmonary disease
(COPD). The Hemolung integrates blood pump and
gas exchange membrane into a single unit
(Figure 2b). Blood flows centrally into a rotating
core, is radially pumped through a stationary












Figure 2 Schematic representation of the three commercially availaban outlet port. The system has not been designed for
oxygenation and is generally recommended for
COPD patients as a primary indication.
4. The Decap® system (Hemodec, Salerno, Italy) uses a
membrane lung connected in series with a
hemodialysis filter and roller pump (Figure 2c).
Ultrafiltrate from the filter is returned to the blood
stream prior to the membrane lung inflow,
allowing additional CO2 removal. Consequently,
smaller membrane lungs can be used (0.3 to
1.35 m2) with lower flow rates (< 500 ml/min).
This configuration is useful for patients requiring
both pulmonary and renal support and is a unique
feature of the Decap.
Rationale for the use of ECCO2R in ARDS
Experimental evidence
Recent experimental studies have demonstrated that
new generations of VV-ECCO2R devices are highly effi-
cient at CO2 removal. A 50% reduction in minute venti-
lation was obtained in healthy mechanically ventilated
swine while maintaining normocarbia using the Hemo-
lung system [13]. In this study, a 15-F dual-lumen cath-
eter was inserted in the external jugular vein and
connected to the Hemolung system. Minute ventilation
was reduced from 5.6 l/min at baseline to 2.6 l/min 2 h
after device insertion and was kept low until the end of
the study, while normocarbia (PaCO2 35–45 mm Hg)
was maintained. CO2 removal by Hemolung remained
steady over 72 h, averaging 72 ± 1.2 ml/min at blood
flows of 447 ± 5 ml/min. After insertion, O2 consump-
tion did not change; CO2 production by the lung de-
creased by 50% and stayed at that level (p < 0.001).
Plasma-free hemoglobin did not change during the
course of the study signifying the safety of the device
with respect to hemolysis [13]. In this study, ECCO2R
using the Hemolung permitted significant CO2 removal










le types of CO2 removal devices. UF: ultrafiltrate.
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tinuous heparin infusion.
The hemodynamic effects of CO2 removal seem to be
beneficial by decreasing pulmonary hypertension and
improving RV-arterial coupling in an experimental
model of ARDS. In a recent study, we sought to deter-
mine whether low-flow CO2 removal therapy used at an
early stage of ARDS could have beneficial hemodynamic
effects on the pulmonary circulation. This study was
performed in an experimental model of ARDS in pigs.
ARDS was obtained by repeated bronchoalveolar lavage
(BAL, 0.09% saline solution). Protective ventilation at
low tidal volume was then established according to the
ARDSNet study. Drainage (12 F) and re-infusion (10 F)
cannulae were inserted into the inferior and the superior
vena cava, respectively. These cannulae were connected
to the PALP system for CO2 removal. ARDS induced se-
vere hypercapnic acidosis with significantly increased
pulmonary artery pressure (PAP). After the PALP was
started, acidosis was rapidly corrected and normocarbia
was maintained despite protective ventilation. PAP sig-
nificantly decreased and a significant drop in Ea was ob-
served during PALP therapy (Figure 3). Mean blood flow
through the PALP was 0.645 l/min and sweep gas flow
was 8 l/min. RV-arterial coupling assessed by the ratio
of Ees on Ea was improved [38].
Other promising approaches for efficient CO2 removal
are still in development [39,40]. Novel methods to
maximize CO2 removal, such as regional blood acidifica-
tion which increases the bioavailability of CO2 by un-
binding it from the bicarbonate ion in circulating blood,
are also under investigation [40].
Clinical evidence
There is accumulating evidence that VV-ECCO2R can
effectively reduce PaCO2 in patients with ARDS and that
VV-ECCO2R facilitates a lung-protective ventilation
strategy by allowing a reduction in tidal volume and in-







Figure 3 Effects of PALP (‘Pump Assisted Lung Protection’, Maquet, G
an experimental model of acute respiratory distress syndrome (ARDSVV-ECCO2R to facilitate ‘ultraprotective’ ventilation [15].
They recruited 32 patients with early (< 72 h) ARDS and
ventilated them according to the ARDSNet protocol for
72 h, at which point the tidal volume was reduced from 6
to 4 ml/kg in all patients (n = 10) who had a plateau pres-
sure of between 28 and 30 cmH2O, thus facilitating fur-
ther reductions in plateau pressures. VV-ECCO2R using
the Decap device successfully treated the hypercapnic
acidosis in all cases and allowed the plateau pressure to be
lowered to 25 cmH2O (4 ml/kg tidal volume and higher
levels of positive end-expiratory pressure [PEEP]) while
mitigating the resultant changes in pH and PaCO2. The
study also demonstrated a reduction in bronchoalveolar
inflammatory cytokines (IL-6, IL-8, IL-1b, IL-1 receptor
antagonist [IL-Ira]) in the Decap group. There were no
harmful effects related to the ultra-protective ventilation
strategy or the VV-ECCO2R. Although this study was un-
controlled and small, it suggests that there may be benefit
to an ultra-protective ventilation strategy facilitated by
VV-ECCO2R within 72 hours of diagnosing ARDS. A
similar approach was taken by another group using the
NovaLung device in arterio-venous configuration. In the
prospective randomized Xtravent-study, Bein et al. [42]
demonstrated that use of very low tidal volumes (3 ml/kg
PBW) combined with extracorporeal elimination of CO2
was feasible without major side effects and might be bene-
ficial in the treatment of patients with severe ARDS. Al-
though that study did not show a mortality benefit,
ventilator-free days assessed at 28 and 60 days were sig-
nificantly higher in the ECCO2R group. Adjunct use of
ECCO2R and mechanical ventilation facilitated liberation
of patients from excessive sedation and increased levels of
spontaneous breathing. Thus, integration of spontaneous
breathing into the management of patients with ARDS
might be easier and more comfortable with extracorporeal
CO2-removal, and a reduced demand for sedative and an-
algesic medication could be advantageous [42]. Forster
et al. [43] demonstrated, in a small series of 10 patients,
that low-flow CO2 removal integrated into a renal-              180                    240                   300
Time (min)
ALP on PALP off
ermany) therapy on systolic pulmonary artery pressure (PAP) in
).
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vasopressor requirements. The gas exchanger was inte-
grated into the continuous hemodialysis system after the
dialysis filter. The authors used a 13.5-F double-lumen
catheter placed in the jugular vein. Similarly, we reported
a case of refractory hypercapnia in a severely burned adult
treated with a simplified VV-ECCO2R technique [44]. We
integrated a pediatric oxygenator into a continuous veno-
venous hemofiltration circuit. This technique, used for at
least 96 h, was feasible and efficiently removed up to 32%
of CO2. Future studies are required to determine whether
‘ultraprotective’ ventilation with adjunct use of ECCO2R
will improve survival in patients suffering from moderate
to severe ARDS. At this time, the effect of ECCO2R on
survival in patients with ARDS is accumulating but is not
yet conclusive [15,42,45].
There are clinical trials planned for several of the new
ECCO2R devices. The rationale for adjunct use of
ECCO2R will depend on the clinical situation in each indi-
vidual patient. However, with the new Berlin definition of
ARDS, the therapeutic window for ECCO2R in ARDS may
be expanded [46]. Because the intensity of therapeutic
intervention increases proportionally to the level of hyp-
oxemia, adjunct use of ECCO2R will likely be considered
at earlier stages of ARDS, for example when the PaO2/
FiO2 ratio is < 200. At that time, ECCO2R could be initi-
ated in combination with tidal volume reduction in order
to achieve ultraprotective ventilation. This approach will
need to be tested in prospective randomized fashion but
the preliminary evidence suggests that, at least in some pa-
tients with slow ARDS progression, this early intervention
may be of use. A few areas of concern remain for both
ECCO2R and ECMO alike, including cannula thrombosis,
need to exchange membranes due to thrombosis and
pump malfunction [45]. Intense research is oriented to-
ward solution of these problems and major improvements
in anticoagulation protocols and updates to clinical prac-
tice guidelines are expected as the results of this research
become available. In our opinion, alternative anticoagula-
tion approaches, such as the work by Cardenas et al. utiliz-
ing regional citrate anticoagulation, could provide a
promising solution to future ECCO2R approaches, espe-
cially in line with the tendency for developing modular
therapeutic solutions permitting concomitant lung and
renal interventions [39,47]. Other novel approaches are
emerging with respect to heparin-free antibody-based in-
terventions to the coagulation cascade as a means to in-
duce thromboprotection during extracorporeal circulation
[48]. Specific anticoagulation requirements for low-flow
systems must be studied systematically and will be the
cornerstone of further acceptance of ECCO2R as well as
full ECMO into daily practice, especially in patients with
ARDS due to multiple trauma and burns, in whom
heparinization is not desired.Conclusion
ARDS remains a life-threatening condition with long-
term consequences in survivors. Protective ventilation
reduces alveolar stress and strain and clearly improves
mortality. However, these beneficial effects are tempered
by the fact that low tidal volume ventilation induces
hypercapnic acidosis responsible for deleterious effects.
Uncoupling between impaired RV function and in-
creased pulmonary vascular tone enhanced by hypercap-
nic acidosis and positive pressure ventilation is a starting
point in the downward spiral of ARDS patients. New
generation ECCO2R therapy can be seen as a low impact
and safe ‘respiratory dialysis’ allowing control of hyper-
capnia and acidosis. ECCO2R should be considered as a
therapeutic adjunct in moderate to severe ARDS, com-
bined with further decrease in tidal volume. Recent
major technological improvements in devices make
them simpler, safer, less invasive and more efficient, re-
quiring lower blood flow rates and smaller access cannu-
las with reduced anticoagulation requirements. However,
while the efficiency of modern ECCO2R devices has
been clearly demonstrated in experimental and clinical
settings, current evidence on their impact on survival in
ARDS is just accumulating and more data will be needed
before these techniques can be incorporated into routine
use.
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